09:02 AM EST, 12/12/2024 (MT Newswires) -- Pfizer ( PFE ) and Alliance Foundation Trials said Thursday that results from a phase 3 trial of the drug Ibrance showed that adding it to standard-of-care therapies extended median progression-free survival by over 15 months in patients with metastatic breast cancer.

The study involved patients with hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer, according to a joint statement.

It showed a median progression-free survival of 44.3 months for 261 patients treated with Ibrance in combination with anti-HER2 therapy and endocrine therapy, compared with a median PFS of 29.1 months for 257 patients treated with anti-HER2 therapy and endocrine therapy alone, Pfizer ( PFE ) and AFT said.

Pfizer ( PFE ) is providing funding support for the trial, which is sponsored by AFT and cancer research groups in the US, Germany, Italy, Spain, Australia, and New Zealand.